Global Sepsis Therapeutics Market Size (2024 - 2029)

Sepsis Therapeutics Market Analysis

The sepsis therapeutics market is projected to register a CAGR of 7.6% over the forecast period.

The COVID-19 pandemic affected the treatment and diagnostics procedures other than COVID-19 which had a significant impact on the studied market. The COVID-19 virus was also added to the list of pathogens that cause sepsis. For instance, an article titled "Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19" published in Frontiers in Immunology Journal in February 2021 stated that both SARS-CoV-2 infection and sepsis shared many pathophysiological and clinical features. Managing COVID, in the beginning, followed the sepsis management guidelines. Most patients who were critically ill with COVID-19 developed sepsis, a significant threat to their survival. Overall, the COVID-19 pandemic is anticipated to have had a positive impact on the market studied.

Sepsis can result from an infection anywhere in the body, such as pneumonia, influenza, or urinary tract infections. The COVID-19 pandemic increased surveillance of the infectious virus among people. Various countries, along with testing for COVID-19 in the test sample given by the symptomatic patient, were also testing for influenza virus, which is a major reason of sepsis. The increased diagnosis of bacterial and viral infection is expected to affect the market in a positive way, as people became aware about the sepsis therapeutics and company activities also increased. Hence COVID-19 viral infection worldwide is bolstering the need to expedite the research and development activities to develop sepsis therapeutics and ultimately augmenting the market growth.

In addition, the increasing incidence of sepsis, high prevalence of sepsis in infants, and rise in the number of pipeline products, and a surge in research and development expenditures are actively affecting the growth of the studied market.

The engagement of pharmaceutical companies and healthcare institutions in research and development activities to develop a noval treatment for sepsis is projected to augment the market growth. For instance, in October 2021, Matinas BioPharma initiated dosing in phase 1 study of one of the first oral aminoglycoside antibiotic drugs MAT2501. The surge in clinical trial activities is likely to augment the market growth.

Additionally, the funding by the government to expedite research activities for sepsis management is likely to create awareness about the disease among the population and ultimately boost market growth. For instance, according to the Canadian Institutes of Health Research July 2020 report, the Government of Canada invested USD 5.7 million to support Sepsis Canada, a new national research network that is expected to improve the treatment and recovery of sepsis patients. 190 clinicians, scientists, and patient representatives from all over Canada came together as part of Sepsis Canada. Such initiatives are anticipated to augment the market growth.

Therefore, owing to the abovementioned factors, the studied market is anticipated to witness growth over the analysis period. however, a lack of an initial diagnostic test for identifying sepsis conditions and a lack of awareness are likely to impede the market growth.

Sepsis Therapeutics Industry Segmentation

As per the scope of the report, sepsis occurs when the body's response to an infection injures its own tissues and organs, potentially leading to death or significant morbidity. The sepsis therapeutics market is segmented by Drug Class (Aminoglycosides, Cephalosporin, Glycopeptide Antibiotics, and Others), Route of Administration (Intravenous and Oral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.